Slide 1: Welcome to the 4Q24 webinar
Welcome to the 4Q24 webinar February 21, 2025
Slide 2: Today's agenda
Today’s agenda ▪ 4Q24 in brief ▪ Highlights of the Q4 ▪ R&D pipeline progress ▪ Implementation of the strategy ▪ Outlook ▪ Summary ▪ Q&A
Slide 3: - She
- She 6.2 RS = 2 7 oO. ‘modulight
Slide 4: We fight cancer with science and technology
This is Modulight We fight cancer with science and technology ▪ We are a biomedical company ▪ We also manufacture products that designs and manufactures for other high-value applications laser devices for the treatment such as flow cytometry, quantum of cancer and eye diseases and computing and digi
Slide 5: Q4 in brief
Q4 in brief ▪ PPT's business developed rapidly in Q4 making total number of hospitals using our platform devices 47 and cadence for 2025 improved ▪ Order collection has increased every quarter during FY24, EUR 2,970 thousand and same continues in early 2025 The operating cash flow ▪ Cash flow from o
Slide 6: Financial highlights October–December 2024
Financial highlights October–December 2024 ▪ Our order collection increased every quarter this year to EUR 2,970 thousand in Q4 ▪ Both operating cash flow 819 (-1,832) thousand & net cash flow -1,144 Revenue EBITDA EBIT (-3,231) thousand significantly improved YoY ▪ Revenue was 40% more than in the
Slide 7: Financial highlights January–December 2024
Financial highlights January–December 2024 Revenue EBITDA EBIT ▪ Revenue was EUR 4,095 (4,025) thousand ▪ EBITDA was EUR -4,836 (-8,539) thousand EUR EUR EUR ▪ EBIT was EUR -8,337 (-12,132) thousand 4,095 -4,836 -8,337 ▪ Operating cash flow was EUR -825 (-7,281) thousand thousand thousand thousand ▪
Slide 8: Key figures
Key figures Group EUR 1,000 unless otherwise noted 10–12/2024 10–12/2023 7–12/2024 7–12/2023 1–12/2024 1–12/2023 1) Revenue 1,431 1,019 2,071 1,425 4,095 4,025 EBITDA -1,023 -2,992 -2,301 -5,529 -4,836 -8,539 EBITDA - % -71.5 % -293.6% -111.1 % -388.0% -118.1 % -212.1% Operating result (EBIT) -2,204
Slide 9: Growth in the R&D pipeline
▪ R&D pipeline remained at 30 (28) Growth in the R&D pipeline projects – aim in all projects is to commercialize our own products ▪ Growing pre-production orders related to the R&D pipeline reflect Number of projects with commercialization potential maturation of the pipeline ▪ New customers and new
Slide 10: Modulight's customer base
Modulight’s customer base Customer maturity Customer ownership continues to improve 35 30 ▪ 37% have over 1bn revenue ▪ 60% of customers are listed 25 companies 20 ▪ 57% are established companies 15 ▪ 33% are privately owned 10 ▪ 7% are research companies 5 0 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23
Slide 11: Revenue model
Revenue model The objective is revenue, based on the Customized R&D projects based on the Best Efforts share of pharmaceutical or Pay Per principle, without revenue risk for Modulight Treatment fees, or the utilization rate of industrial applications. Predictability of Modulight’s revenue is improvi
Slide 12: Strategy and targets
Strategy and targets Extension of the offering to new Commercial and indications and applications operational excellence Geographical New business State-of-the-art laser expansion models technology expertise
Slide 13: Geographical expansion
Geographical expansion ▪ Investments in geographical expansion continued and has resulted in increased Modulight seeks growth business in US especially in the US market, ▪ Presence in the US market is strengthening with where the company has both local sales and clinical support. This is best been i
Slide 14: New business models
New business models ▪ Several leading hospitals from both the East and West Coast regularly use Modulight’s technology with the PPT Modulight strongly seeks model growth through SaaS-based ▪ The implementation of the pay per business models, such as treatment (PPT) business model the Pay Per Treatme
Slide 15: New indications and applications
New indications and applications ▪ More customers & leads with synergies to Modulight aims to expand existing customers & indications its offering to cover other ▪ UTUC P3 indications as well as ▪ Glioblastoma – early stage extend the use of its medical device platform. ▪ Ophthalmology ▪ Other high-
Slide 16: Commercial and operational excellence
Commercial and operational excellence ▪ Focus on operational efficiency improved operating margins ▪ Less work on taking in use new Modulight aims to develop machinery has resulted to its commercial and more R&D and Sales & operational expertise as Marketing resources well as the ESG, governance and
Slide 17: State-of-the-art laser technology expertise
State-of-the-art laser technology expertise ▪ Already completed investment program continues to benefit us more and more and generates positive customer feedback about Modulight continues our capabilities to supply & differentiate. This investments into high value is also visible now in the orderboo
Slide 18: Outlook
Outlook Most of Modulight’s customer projects are various types in the early stages of development. These projects are focused on commercializing Modulight’s own products. In line with its strategy, Modulight is also transitioning from device delivery-based payments to a new treatment-session-based
Slide 19: Summary
Summary ▪ PPT model implementation progress – install base now 50 hospitals – continue increasing number of sites but also more on per site usage ▪ R&D pipeline at 30 projects and focus to more mature projects ▪ 3.0m€ new orders received during Q4 – maturing customer projects & increasing utilizatio
Slide 20: Thank you! Questions?
Thank you! Questions?